Progyny
PGNY
27.55
+1.64
+6.33%
Progyny
US · PGNY
#2809 by market cap
Listed 2019
27.55
+1.64
+6.33%
Live - 5344 symbols - heartbeat 482s ago
· 2026-10-08 06:31
Pre-market
27.55
0.00%
After-hours
28.09
+1.96%
- Market cap
- 2.11B
- P/E (TTM)i
- 29.95
- P/Bi
- 4.66
- EPSi
- 0.65
- Div yieldi
- 0.00%
- 52W posi
- 67%
Reader sentiment
Are you bullish or bearish on PGNY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.66, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +10.40% YoY
Margins
- Gross margin
- 23.63%
- Operating margin
- 6.62%
- Net margin
- 4.54%
Key ratios & quality
- PEG ratioi
- 1.22
- Altman Z-Scorei
- 8.66
PEG uses trailing P/E against the 3-year net income growth rate (24.45%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105.40M | 229.68M | 344.86M | 500.62M | 786.91M | 1.09B | 1.17B | 1.29B |
| Gross profit | 19.43M | 45.51M | 70.06M | 112.14M | 167.33M | 238.80M | 253.36M | 304.48M |
| Selling & admin expenses | 22.89M | 35.83M | 61.71M | 79.80M | 143.98M | 176.62M | 185.91M | 219.21M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -3.45M | 9.68M | 8.35M | 32.34M | 23.34M | 62.18M | 67.46M | 85.28M |
| Pretax profit | -6.89M | -8.56M | 8.68M | 32.44M | 24.44M | 70.69M | 83.20M | 95.43M |
| Tax | -1.78M | 12.00K | -37.78M | -33.33M | -5.92M | 8.65M | 28.87M | 36.91M |
| Net profit | 661.00K | -8.57M | 46.46M | 65.77M | 30.36M | 62.04M | 54.34M | 58.52M |
| Basic EPS | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Diluted EPS | -0.08 | -0.41 | 0.47 | 0.66 | 0.30 | 0.62 | 0.57 | 0.65 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 324.04M | 332.87M | 313.35M | 318.40M | 328.50M | 350.51M |
| Gross profit | 75.80M | 78.97M | 72.84M | 76.88M | 83.07M | 89.30M |
| Selling & admin expenses | 51.63M | 54.62M | 51.31M | 61.66M | 47.69M | 49.30M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 24.17M | 24.36M | 21.53M | 15.22M | 35.38M | 40.00M |
| Pretax profit | 26.54M | 27.08M | 23.96M | 17.85M | 36.88M | 41.14M |
| Tax | 11.48M | 9.97M | 10.10M | 5.37M | 12.65M | 13.09M |
| Net profit | 15.06M | 17.11M | 13.86M | 12.49M | 24.23M | 28.05M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.17 | 0.19 | 0.15 | 0.14 | 0.29 | 0.34 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 24.54M | 132.44M | 190.22M | 258.54M | 433.86M | 640.41M | 472.72M | 551.78M |
| Cash & ST investments | 127.00K | 80.38M | 109.30M | 119.42M | 189.30M | 371.09M | 227.95M | 310.10M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 41.32M | 150.43M | 253.93M | 358.07M | 542.99M | 756.62M | 607.10M | 742.44M |
| Total current liabilities | 30.20M | 36.16M | 77.79M | 98.82M | 159.54M | 185.95M | 168.63M | 202.39M |
| Short-term debt | 253.00K | -- | 1.23M | 1.23M | 1.23M | 2.15M | 2.86M | 3.73M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 30,202,000.00 | 36,163,000.00 | 86,980,000.00 | 106,243,000.00 | 166,018,000.00 | 203,191,000.00 | 185,040,000.00 | 226,391,000.00 |
| Total equity | 11.12M | 114.27M | 166.95M | 251.82M | 376.97M | 553.43M | 422.06M | 516.04M |
| Retained earnings | -104.85M | -113.48M | -68.19M | -2.42M | 27.93M | 89.97M | 144.31M | 202.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 567.69M | 594.40M | 622.01M | 551.78M | 501.55M | 513.02M |
| Cash & ST investments | 256.12M | 305.09M | 345.21M | 310.10M | 225.11M | 236.93M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 730.29M | 760.95M | 795.23M | 742.44M | 698.34M | 715.84M |
| Total current liabilities | 237.13M | 220.42M | 210.49M | 202.39M | 235.74M | 240.08M |
| Short-term debt | -- | -- | -- | 3.73M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 263,126,000.00 | 245,928,000.00 | 235,223,000.00 | 226,391,000.00 | 258,993,000.00 | 262,579,000.00 |
| Total equity | 467.16M | 515.02M | 560.00M | 516.04M | 439.34M | 453.26M |
| Retained earnings | 159.37M | 176.48M | 190.34M | 202.83M | 227.06M | 255.11M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.27M | -1.53M | 36.20M | 26.04M | 80.40M | 188.81M | 179.11M | 210.19M |
| Depreciation & amortization | 1.88M | 2.13M | 1.91M | 1.30M | 1.60M | 2.28M | 3.18M | 4.95M |
| Free cash flow | 1.69M | -4.49M | 35.17M | 23.91M | 77.15M | 185.17M | 173.70M | 191.78M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.21M | 81.04M | -- | -- | 0 | 0 | -300.28M | -81.66M |
| Ending cash balance | 127.00K | 80.38M | 70.31M | 91.41M | 120.08M | 97.30M | 162.31M | 114.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 49.81M | 55.51M | 50.67M | 54.20M | 45.95M | 50.43M |
| Depreciation & amortization | 1.11M | 1.21M | 1.27M | 1.37M | 1.48M | 1.62M |
| Free cash flow | 46.97M | 50.24M | 45.99M | 48.59M | 39.60M | 44.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | -81.66M | -118.61M | -30.02M |
| Ending cash balance | 114.24M | 137.54M | 139.98M | 114.19M | 133.57M | 154.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -89.47 | 33.04 | 31.41 | 9.66 | 13.34 | 11.14 | 12.48 |
| ROA %i | -14.53 | -8.94 | 22.98 | 21.49 | 6.74 | 9.55 | 7.97 | 8.67 |
| ROIC %i | -- | -89.47 | 31.20 | 30.10 | 9.41 | 12.96 | 8.70 | 10.62 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -0.40 | 19.72 | 15.60 |
| EBIT margin %i | -3.28 | 4.21 | 2.42 | 6.46 | 2.97 | 5.71 | 5.78 | 6.62 |
| FCF / sales %i | 1.61 | -- | 10.20 | 4.78 | 9.80 | 17.01 | 14.88 | 14.88 |
| Current ratioi | 0.81 | 3.66 | 2.45 | 2.62 | 2.72 | 3.44 | 2.80 | 2.73 |
| Quick ratioi | 0.78 | 3.52 | 2.38 | 2.57 | 2.69 | 3.30 | 2.75 | 2.62 |
| Debt / assetsi | 0.61 | 0.00 | 3.76 | 2.42 | 1.42 | 2.56 | 3.17 | 3.73 |
| LT debt / equityi | -- | -- | 4.98 | 2.95 | 1.72 | 3.12 | 3.89 | 4.65 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 92.18 | 68.10 | 50.75 | 46.69 | 32.60 | 17.87 |
| Net income CAGR (3Y) %i | -- | -- | -- | 363.38 | -- | 10.12 | -6.17 | 24.45 |
| FCF CAGR (3Y) %i | -- | -- | -- | 141.71 | -- | 73.97 | 93.68 | 35.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 10.11 | 10.94 | 11.37 | 12.48 | 14.94 | 16.24 |
| ROA %i | 6.89 | 7.28 | 7.77 | 8.67 | 9.48 | 10.65 |
| ROIC %i | 8.14 | 9.01 | 9.49 | 10.62 | 12.92 | 14.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.03 | 6.18 | 6.77 | 6.62 | 7.46 | 8.55 |
| FCF / sales %i | 16.14 | 15.31 | 15.25 | 14.88 | 14.26 | 13.61 |
| Current ratioi | 2.39 | 2.70 | 2.96 | 2.73 | 2.13 | 2.14 |
| Quick ratioi | 2.34 | 2.62 | 2.84 | 2.62 | 2.07 | 2.06 |
| Debt / assetsi | 3.56 | 3.35 | 3.11 | 3.73 | 3.33 | 3.14 |
| LT debt / equityi | 5.57 | 4.95 | 4.42 | 4.65 | 5.29 | 4.96 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Fertility benefits services revenue is the largest reported line at 65.68% of revenue, across 2 reported segments.
- Pharmacy benefits services revenue follows at 34.32%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Fertility benefits services revenue65.68%
Pharmacy benefits services revenue34.32%
Quote time 2026-10-08 06:31:40 · For reference only, not investment advice and not tailored to your situation.